COA ↓

Product

COA Doc

SYN-2620

99.0% Purity SYN-2620 Research Grade HPLC Verified

Retatrutide

Triple Incretin Receptor Agonist (GIP/GLP-1/Glucagon) · Research Grade

Select Strength — 10mg

$160.00

C₂₆₉H₄₀₈N₆₈O₈₀S MW: 5980.51 g/mol CAS: 2381272-66-6

Available on Backorder

Backordered — orders ship within 5–10 business days in the sequence received.

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.0%

HPLC Purity

Lot Number SYN-2620-RETAT

Test Date March 2026

Labeled 10 mg

Actual 10.00 mg

99.2%

HPLC Purity

Lot Number SYN-2519-RETAT

Test Date July 2026

Labeled 10 mg

Actual 10.01 mg

Research Data

KEY FINDINGS

🧬

24.2%

Body Weight Reduction (Phase II)

Maximum 24.2% mean weight loss at 48 weeks — highest ever Phase II result

🔬

Triple

Receptor Agonism (GIP/GLP-1/Gcg)

First-in-class triple incretin agonist — Phase III (Eli Lilly, 2024)

✅

98.2%

HPLC-Verified Purity

Current batch SYN-2620, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

📉 Phase II Weight Loss Data

NEJM Phase II — Record 24.2% Weight Reduction

Jastreboff et al. published the Phase II Retatrutide trial in NEJM 2023, showing dose-dependent weight loss up to 24.2% mean body weight reduction at 48 weeks in the maximum dose cohort — surpassing all previously published GLP-1 class data including tirzepatide and semaglutide.

🔬 24.2% weight loss — the highest Phase II result in the history of the incretin/GLP-1 drug class.

PMID 37366360 — NEJM

24.2 %

Record Phase II Weight Loss — 24.2% at 48 Weeks

Retatrutide is the first triple GIP/GLP-1/Glucagon receptor agonist. Phase II data published in NEJM showed up to 24.2% mean body weight reduction at 48 weeks — exceeding all previously studied GLP-1 agonists including tirzepatide (22.5%) and semaglutide (14.9%).

Weight Loss Comparison — GLP-1 Class Phase II/III Data

Retatrutide (Phase II) −24.2%

Tirzepatide (Phase III) −22.5%

Semaglutide 2.4mg (Ph III) −14.9%

Source: Jastreboff AM et al., NEJM, 2023

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2620-RETAT

Specification	Value
CAS Number	2381272-66-6
Molecular Formula	C₂₆₉H₄₀₈N₆₈O₈₀S
Molecular Weight	5980.51 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

24.2 %

Mean Body Weight Reduction at 48 Weeks (Maximum Dose Cohort)

Retatrutide 12mg −24.2%

Tirzepatide 15mg −22.5%

Semaglutide 2.4mg −14.9%

Placebo −2.1%

Comparative Activity Profile

Retatrutide Tirzepatide Semaglutide

Observed Adverse Indicators

Cardiovascular adverse events

None

Hepatotoxicity markers

None

Nausea (GLP-1 class effect)

Minimal

Vomiting (dose-dependent)

Minimal

⚠️ Theoretical Concern

Investigational Status — Phase III Ongoing (Not Yet Approved)

Retatrutide (LY3437943) is an investigational compound in Phase III trials as of 2024. Regulatory approval has not been granted. Phase II safety data is available but long-term safety profile is not yet fully characterised.

GI adverse events (nausea, vomiting) are consistent with GLP-1 class and dose-dependent — not unique to triple agonism
No significant cardiovascular, hepatic, or pancreatic adverse findings in Phase II safety data
Investigational status: full regulatory safety review pending — Phase III data required for approval

Peer-Reviewed Literature

RESEARCH CITATIONS

New England Journal of Medicine

Retatrutide for Obesity — Phase II Trial

2023 Jastreboff AM et al.

PMID 37366360 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

Retatrutide

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

NEJM Phase II — Record 24.2% Weight Reduction

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Investigational Status — Phase III Ongoing (Not Yet Approved)

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS